U.S. markets open in 6 hours 58 minutes

Daxor Corporation (DXR)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
10.05-0.03 (-0.30%)
At close: 3:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Previous Close10.08
Open10.13
Bid0.00 x 900
Ask10.14 x 1000
Day's Range10.05 - 10.13
52 Week Range9.07 - 24.08
Volume4,384
Avg. Volume12,091
Market Cap40.54M
Beta (5Y Monthly)-1.02
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 05, 2018
1y Target Est21.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Daxor Biotech Blood Volume Innovation Is Rapidly Improving Patient Outcomes
    Benzinga

    Daxor Biotech Blood Volume Innovation Is Rapidly Improving Patient Outcomes

    Daxor Corporation (NYSE: DXR) President and CEO Michael Feldschuh participated in the Benzinga Biotech Small Cap Conference held on March 24, 2021. He provided an overview on Daxor’s business model and growth strategy, including updates on groundbreaking research and product development as well as new prospective medical trials. Daxor Corporation continues to make news with its breakthrough technology focusing on blood volume measurement innovation. The company developed and markets the BVA-100® (Blood Volume Analyzer), the first and only diagnostic blood test cleared by the Food and Drug Administration (FDA) to provide safe, accurate, objective quantifications of blood volume status and composition compared to patient-specific norms for use in a variety of medical and surgical conditions including heart failure and critical care – an addressable market of over $12 Billion. Daxor’s blood volume analysis test is positioned to disrupt the massive heart failure market of over 6 million patients in the U.S. alone, one million of whom will be hospitalized this year. Over 50,000 blood tests have been performed at leading hospitals across the country since its introduction and a recent peer-reviewed study has shown the test to reduce heart failure mortality by over 80% and readmissions by over 56%, confirming that accurate blood volume measurement enhances hospital performance metrics and leads to better patient outcomes. The test is administered at the point of care and results are ready within an hour or less after lab processing. Additional use of the test has been reported in the areas of critical care as well as COVID-19 management. Peer-reviewed publication of a randomized controlled trial showed a 66% reduction in ICU mortality when blood volume analysis was used to guide care in critically ill patients. This also represents a significant market for Daxor to tackle as care decisions in transfusion and resuscitation are made for millions of patients each year. Daxor’s technology is poised to make a significant impact on a broad array of conditions throughout the care continuum in both the inpatient and outpatient settings, giving an opportunity for significant recurring revenue as it scales in addressable markets. Daxor has been officially recognized as meeting all ISO 13485 requirements, including medical devices, Quality Management System Certification ensuring the consistent design, development, production, installation, and delivery for the BVA-100 system. “This ISO certification opens the way for Daxor to international distribution by meeting all its rigorous requirements. This is a proud achievement for us,” said Michael Feldschuh, President and CEO of Daxor Corporation. “Being recognized as meeting the “gold standard” for quality enables us to expand the availability of our products outside the U.S. and amplify the efforts currently underway domestically through our sales force expansion and third-party distribution partners.” Daxor has experienced tremendous success in its recent technology and on-going research, resulting in: Diagnostic division revenue growth of 50% in 2020 Multi-channel distribution through its direct sales force, domestic distributors, future international distribution and U.S. military contracts Clean capital structure, strong balance sheet, no warrants and small float Reimbursement with CPT/APC coding for inpatient and outpatient use by public and private insurance Development of a rapid, rugged, portable blood volume analyzer slated for FDA submission in 12 months for both military and civilian use as well as a novel patent-pending fluorescent tracer which will vastly broaden the care settings that the test can be administered Published health-economic analysis showing Daxor’s test to be extremely cost-effective, providing excellent value to health systems while saving lives and reducing costs Initiation of 2 randomized control trials to guide volume treatment in heart failure & COVID patients – Duke University & NYU, OHSU, Wake Forest Daxor has also earned the trust and investment of the Department of Defense (DOD) which has awarded four contracts to the company, totaling more than $2 million for the manufacture of advanced blood volume analyzers for military and civilian applications. The latest is a Phase 2 contract from the U.S. Air Force (USAF) to implement a novel fluorescent tracer and optical sensing technology into a next-generation point-of-care blood volume analyzer. Almost one in three military deaths are from a blood hemorrhage, and Daxor is developing a rapid, rugged and portable blood volume analyzer slated for FDA submission by 2022 for both military and civilian use. Daxor was also awarded a grant from CAPCaT for a program run by the Massachusetts Medical Device Development Center (M2D2) and funded by two NIH institutions to develop a smart, point-of-care heart failure diagnostic for quantification of intravascular fluid overload to enable precision diuretic dosing in February 2021. The grant will help further ongoing next generation product development of point-of-care products that are faster, easier to use and valuable in both military and civilian applications. Daxor’s innovation and research have also led the company to some aggressive patent filings and activity as it continues to look for new patient innovation and subsequent sales opportunities including: Six new patents filed by Daxor including the novel fluorescent tracer Five new patents anticipated for 2021 Awarded 4 U.S. patents and 7 patents pending plus numerous international patents (Europe, Japan, Canada, among others via WIPO PCT) The point-of-care diagnostics market is projected to grow to $46.7 billion by 2024. Factors such as increasing global incidence of target conditions, growing government support, and rising preference for home healthcare drive market growth and position Daxor in an enviable space. Photo by National Cancer Institute on Unsplash See more from BenzingaClick here for options trades from BenzingaGeneral Mills CEO On Shrimpgate: 'Highly Unlikely' This Happened At Company FacilityCould Long-Term Capital Gains Selling Be Weighing On The Market?© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • DAXOR CORPORATION TO PARTICIPATE IN BENZINGA BIOTECH SMALL CAP CONFERENCE
    GlobeNewswire

    DAXOR CORPORATION TO PARTICIPATE IN BENZINGA BIOTECH SMALL CAP CONFERENCE

    NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will participate in the Benzinga Biotech Small Cap Conference to be held March 24th to 25th, 2021. Mr. Feldschuh will present on March 24th at 12:30 PM EDT. Mr. Feldschuh will provide an overview on the Company’s business model and growth strategy, including updates on ground-breaking research and product development, contracts with the US Department of Defense, grant funding through the National Institute of Health, and new prospective medical trials using Daxor BVA-100® blood test in the management of critical care, COVID-19, and heart failure. Investors can view Mr. Feldschuh’s general corporate presentation once they register for the conference, and an archived replay of the presentation will be available via the conference website. Investors can also request a one-on-one meeting with Mr. Feldschuh following the conclusion of the conference. Event: Benzinga Biotech Small Cap ConferenceDate: March 24th, 2021 at 12:30 PM EDTRegister here. Interested investors can contact Bret Shapiro at COREIR either by calling 1-516-222-2560 or emailing brets@coreir.com. About Daxor CorporationDaxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Forward-Looking Statements Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:Bret ShapiroSr. Managing Partner, CORE IR516-222-2560brets@coreir.com

  • Daxor to Participate in the Maxim Group 2021 Emerging Growth Virtual Conference
    GlobeNewswire

    Daxor to Participate in the Maxim Group 2021 Emerging Growth Virtual Conference

    NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at Maxim Group 2021 Emerging Growth Virtual Conference to be held March 17-19, 2021, 9:00 AM - 5:00 PM EST. Mr. Feldschuh will highlight the many recent accomplishments of the Company including accelerating revenue, groundbreaking research and product development, contracts with the US Department of Defense, grant funding through the NIH, and new prospective medical trials for the use of Daxor’s BVA-100® blood test in the management of critical care, COVID-19, and heart failure with leading institutions. Investors can view Mr. Feldschuh’s general corporate presentation once they register for the conference, and an archived replay of the presentation will be available via the conference website. Investors can also request a one-on-one meeting with Mr. Feldschuh following the conclusion of the conference. Event: Maxim Group’s Inaugural Emerging Virtual ConferenceDate: March 17th -19th, 9:00 AM - 5:00 PM ESTRegister here. Interested investors can contact Bret Shapiro at COREIR either by calling 1-516-222-2560 or emailing brets@coreir.com. About Daxor CorporationDaxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Investor Relations Contact:Bret ShapiroSr. Managing Partner, CORE IR516-222-2560brets@coreir.com